Weight Management

Weight loss of at least 5% to 10% for persons with T2D is realistic and essential, says Nisa Maruthur, MD, MHS, coauthor of the new ADA/EASD consensus report.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

Phase II clinical trial shows a fixed dose combination of semaglutide/cagrilintide reduces HbA1c and weight much better than either drug alone.

A free, automated online behavioral weight loss program led to a mean 5% reduction in weight over 12 weeks without clinician involvement, a new study reports.

Excess weight diminishes the development and function of the musculoskeletal system at any point in the lifespan. An obesity specialist highlights the dangers.

With the iDip program, 50% of adults reached the researchers' goal of losing at least 5% body weight and maintained it for 1 year without strict dieting.

Slide Show: The AHA added sleep duration to its Life's Simple 7 cardiovascular health construct and updated sections on diet, lipids, blood glucose and smoking.

Insurance companies believe the required presurgical programs reduce complications and improve outcomes but a new study strongly suggests the opposite.

ENDO 2022: Findings from the long-term, real-world study of meds for maintenance of meaningful weight loss support wider uptake of the agents, authors say.

ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.

Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.

The Canadian Obesity Society advocates for a therapeutic approach to obesity that removes stigma, focuses on individual patient goals, and favors body health over body weight.

Women, Black individuals, and adults diagnosed with overweight or obesity in more recent years were more likely to receive a referral, according to new study.

The proportion of overweight, obesity, or severe obesity increased from 38% to 45% among 4500 young people seen in a primary care network where most receive public insurance.

The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.

Tirzepatide was associated with reductions in body weight of up to 22.5% over 72 weeks in the global phase 3 registration trial.

Asthma-COPD overlap and obesity mutually exacerbate each other and an early program of pulmonary rehabilitation shows promise to help both.

Persons with type 2 diabetes who either gained or lost 5% of baseline bodyweight were found to be at higher risk for heart failure, MI, and all-cause death.

Having overweight or obesity in midlife was associated with significantly higher cumulative morbidity and health care costs during older adulthood in prospective cohort study.

Nearly two-thirds of persons aged younger than 50 years who had an acute ischemic stroke had obesity in a study presented at the 2022 International Stroke Conference.

Tirzepatide at 3 different doses significantly improved glycemic control and promoted weight loss when added to titrated insulin in patients with type 2 diabetes.

Use of SGLT2 inhibitor and GLP-1 RA therapy in patients with type 2 diabetes appears to confer hepatic protection when compared with use of DPP-4 inhibitors.

Integrating NAFLD as a diabetes complication to be addressed during routine cycles of care could reduce barriers to a NAFLD pathway in primary care, agreed focus group participants.

Using Mendelian randomization, a new study found in particular that waist-hip ratio may be a more important predictor of hospitalization than BMI.

Take this quick quiz to test your knowledge of recent advances most likely to have an impact on weight management in your practice.

Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.

Obesity and its causes are the focus of extensive research evaluating new therapeutic targets. Get an at-a-glance update on progress and FDA approvals during 2021

Weight bias themes in primary care are the subject of contemporary research. Which options you choose to these 8 questions may offer insight into your own unconscious prejudices.